Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,longTermDebt,accountsPayable,otherLiab,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,repurchaseOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,epsCurrentYear,market,shortName,exchange,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,exchangeDataDelayedBy,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,IOVA,647428000.0,152848992,55949000,,-75449000,,-75449000,19621000,0,-75570000,-75570000,,,,,,0,0,75570000,0,121000,,-75449000,-75449000,1552968000.0,103142000.0,647428000.0,750573000.0,6000.0,-905642000.0,96000.0,7247000.0,131954000.0,55059000.0,96000.0,127881000.0,605218000.0,10227000.0,461976000.0,1000000.0,13369000.0,,87916000.0,-15000.0,77211000.0,1000000.0,50364000.0,-8591000.0,49364000.0,65184000.0,-62391000.0,372000.0,21292000.0,-10705000.0,,550159000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,24.31,1630526402,0.23999977,24.22,24.9156,24.05,1308388,-11.576191,4.336,22.688,1.6219997,0.071491525,27.351812,-3.041813,-0.11121065,3715758848,-10.756637,5.6065497,15,America/New_York,EDT,False,False,USD,-2.1,us_market,"Iovance Biotherapeutics, Inc.",NGM,PRE,2,0.9970909,24.05 - 24.9156,24.07,0.0,0.0,9,8,finmb_40424708,NasdaqGM,"Iovance Biotherapeutics, Inc.",USD,2131810,1342257,8.429999,0.5308564,15.88 - 54.21,-29.9,-0.55155873,15.88,54.21,1620331200,1635937140,0,1636372800,-1.85,-2.26,-14400000,0.82,,,54.21,15.88,22.69,27.35,2.13M,1.34M,152.85M,,128.16M,0.62%,106.12%,22.33M,3.85,17.49%,14.61%,19.75M,,,,,,0.00%,,,1:100,"Sep 25, 2013","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-32.09%,-59.60%,,,,,-265.44M,-265.44M,-1.85,,593.93M,3.89,54M,8.34,10.99,4.34,-202.23M,-158.4M,Value,94070,Healthcare,241,9,7,"Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'UniversitÃ© de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.",San Carlos,650 260 7120,CA,7,1609372800,1622505600,8,United States,http://www.iovance.com,86400,8,999 Skyway Road,Biotechnology,Suite 150
t-1,IOVA,656494000.0,152848992,52451000,,-68397000,,-68397000,16083000,0,-68534000,-68534000,,,,,,0,0,68534000,0,137000,,-68397000,-68397000,1486662000.0,111960000.0,656494000.0,768458000.0,6000.0,-830193000.0,19000.0,18443000.0,67329000.0,54871000.0,19000.0,113915000.0,636100000.0,,562108000.0,,13513000.0,11714000.0,82088000.0,-12132000.0,58753000.0,1000000.0,2958000.0,3205000.0,2959000.0,-981000.0,-62692000.0,321000.0,14311000.0,-23335000.0,-1000.0,581229000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,24.31,1630526402,0.23999977,24.22,24.9156,24.05,1308388,-11.576191,4.336,22.688,1.6219997,0.071491525,27.351812,-3.041813,-0.11121065,3715758848,-10.756637,5.6065497,15,America/New_York,EDT,False,False,USD,-2.1,us_market,"Iovance Biotherapeutics, Inc.",NGM,PRE,2,0.9970909,24.05 - 24.9156,24.07,0.0,0.0,9,8,finmb_40424708,NasdaqGM,"Iovance Biotherapeutics, Inc.",USD,2131810,1342257,8.429999,0.5308564,15.88 - 54.21,-29.9,-0.55155873,15.88,54.21,1620331200,1635937140,0,1636372800,-1.85,-2.26,-14400000,0.82,,,54.21,15.88,22.69,27.35,2.13M,1.34M,152.85M,,128.16M,0.62%,106.12%,22.33M,3.85,17.49%,14.61%,19.75M,,,,,,0.00%,,,1:100,"Sep 25, 2013","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-32.09%,-59.60%,,,,,-265.44M,-265.44M,-1.85,,593.93M,3.89,54M,8.34,10.99,4.34,-202.23M,-158.4M,Value,94070,Healthcare,241,9,7,"Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'UniversitÃ© de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.",San Carlos,650 260 7120,CA,7,1609372800,1622505600,8,United States,http://www.iovance.com,86400,8,999 Skyway Road,Biotechnology,Suite 150
t-2,IOVA,711837000.0,152848992,43050000,,-58571000,,-58571000,15916000,0,-58966000,-58966000,,,,,,0,0,58966000,0,395000,,-58571000,-58571000,1473472000.0,70453000.0,711837000.0,782294000.0,6000.0,-761796000.0,155000.0,8910000.0,68310000.0,64390000.0,155000.0,49794000.0,723590000.0,,645838000.0,,24794000.0,2352000.0,-35111000.0,16264000.0,-52955000.0,1000000.0,1166000.0,-11268000.0,1166000.0,-92304000.0,-40515000.0,307000.0,12753000.0,-17844000.0,-1000.0,659200000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,24.31,1630526402,0.23999977,24.22,24.9156,24.05,1308388,-11.576191,4.336,22.688,1.6219997,0.071491525,27.351812,-3.041813,-0.11121065,3715758848,-10.756637,5.6065497,15,America/New_York,EDT,False,False,USD,-2.1,us_market,"Iovance Biotherapeutics, Inc.",NGM,PRE,2,0.9970909,24.05 - 24.9156,24.07,0.0,0.0,9,8,finmb_40424708,NasdaqGM,"Iovance Biotherapeutics, Inc.",USD,2131810,1342257,8.429999,0.5308564,15.88 - 54.21,-29.9,-0.55155873,15.88,54.21,1620331200,1635937140,0,1636372800,-1.85,-2.26,-14400000,0.82,,,54.21,15.88,22.69,27.35,2.13M,1.34M,152.85M,,128.16M,0.62%,106.12%,22.33M,3.85,17.49%,14.61%,19.75M,,,,,,0.00%,,,1:100,"Sep 25, 2013","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-32.09%,-59.60%,,,,,-265.44M,-265.44M,-1.85,,593.93M,3.89,54M,8.34,10.99,4.34,-202.23M,-158.4M,Value,94070,Healthcare,241,9,7,"Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'UniversitÃ© de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.",San Carlos,650 260 7120,CA,7,1609372800,1622505600,8,United States,http://www.iovance.com,86400,8,999 Skyway Road,Biotechnology,Suite 150
t-3,IOVA,758305000.0,152848992,49274000,,-63018000,,-63018000,14353000,0,-63627000,-63627000,,,,,,0,0,63627000,0,609000,,-63018000,-63018000,1461207000.0,59258000.0,758305000.0,817567000.0,6000.0,-703225000.0,317000.0,8707000.0,160614000.0,54905000.0,317000.0,26206000.0,782654000.0,,611265000.0,,10238000.0,2352000.0,-418781000.0,672000.0,-423756000.0,1000000.0,568465000.0,13423000.0,568630000.0,108074000.0,-36635000.0,260000.0,12028000.0,-4975000.0,-165000.0,727749000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,24.31,1630526402,0.23999977,24.22,24.9156,24.05,1308388,-11.576191,4.336,22.688,1.6219997,0.071491525,27.351812,-3.041813,-0.11121065,3715758848,-10.756637,5.6065497,15,America/New_York,EDT,False,False,USD,-2.1,us_market,"Iovance Biotherapeutics, Inc.",NGM,PRE,2,0.9970909,24.05 - 24.9156,24.07,0.0,0.0,9,8,finmb_40424708,NasdaqGM,"Iovance Biotherapeutics, Inc.",USD,2131810,1342257,8.429999,0.5308564,15.88 - 54.21,-29.9,-0.55155873,15.88,54.21,1620331200,1635937140,0,1636372800,-1.85,-2.26,-14400000,0.82,,,54.21,15.88,22.69,27.35,2.13M,1.34M,152.85M,,128.16M,0.62%,106.12%,22.33M,3.85,17.49%,14.61%,19.75M,,,,,,0.00%,,,1:100,"Sep 25, 2013","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-32.09%,-59.60%,,,,,-265.44M,-265.44M,-1.85,,593.93M,3.89,54M,8.34,10.99,4.34,-202.23M,-158.4M,Value,94070,Healthcare,241,9,7,"Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'UniversitÃ© de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.",San Carlos,650 260 7120,CA,7,1609372800,1622505600,8,United States,http://www.iovance.com,86400,8,999 Skyway Road,Biotechnology,Suite 150
